Tags : Treated

BMS’ Revlimid + Rituximab Receives EC’s Approval to Treat Adults

Shots: The approval is based on P-III AUGUMENT study involves assessing of Revlimid + Rituximab (R2) vs rituximab +PBO in patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL) The study resulted improvement in 1EP mPFS (39.4 mos. vs 13.8 mos.) with median follow up 29.2 months. Additionally, the safety and efficacy […]Read More

AstraZeneca Canada’s Calquence (acalabrutinib) Receives Health Canada Approval for Patients

Shots: The NOC is based on the positive data of Calquence in ACE-LY-004 trial demonstrating 81% OR rate for patients with relapsed or refractory MCL The Health Canada approval of Calquence allows AstraZeneca to develop the treatments of blood cancers Calquence (acalabrutinib, previously known as ACP-196) is an oral selective inhibitor of Bruton’s tyrosine kinase (BTK) […]Read More

Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial

Shots: The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg, qd) as monothx in adults patients previously treated, LA or metastatic cholangiocarcinoma with documented FGF/FGFR status divided into 3 cohorts: Cohort A (N=107, FGFR2 fusions or rearrangements), Cohort B (N=20, other FGF/FGFR genetic alterations) or Cohort C (N=18, no FGF/FGFR genetic alterations)   […]Read More